Table 1.
Second-line option in patients with relapsed osteosarcoma.
| Drugs | No | CR + PR | ORR | Authors |
|---|---|---|---|---|
| IFO 2 g/m2/day 1–3 ETO 100 mg/m2/day 1–3 |
32 | 2/3 | 16 | Kung FH, Cancer 1992 [9] |
| IFO 2 g/m2/day 1–3 ETO 100 mg/m2/day 1–3 |
8 | 0/3 | 37 | Miser JS, J Clin Onc 1997 [10] |
| CTX 500 mg/m2/day 1–5 ETO 100 mg/m2/day 1–5 |
14 | 1/3 | 28 | Rodriguez-Galindo C, JPHO 2002 [11] |
| CTX 4000 mg/m2/day ETO 200 mg/m2/day 1–3 |
26 | 2/3 | 19 | Berger M, Cancer, 2009 [12] |
| GEM 900 mg/m2/day, d1,8 TAXO 80–100 mg/m2, d1 |
14 | 0/1 | 7 | Fox E. SARC 003, Oncologist 2012 [13] |
| GEM 675 mg/m2, d 1,8 TAXO 75–100 mg/m2, d1 |
10 | 0/3 | 30 | Navid F, Cancer 2008 [14] |
| GEM 675–900 mg/m2, d 1,8 TAXO 100 mg/m2, d1 |
17 | 3/1 | 24 | Song BS, Pediatr Blood Cancer 2014 [15] |
| GEM 675–900 mg/m2 d1,8 TAXO 75 mg/m2 d1 |
34 | 0/5 | 15 | Palmerini E, BMC Cancer 2017 [16] |
| IFO 2.8 g/m2/day 1–5 | 23 | nr | nr | Chou AJ, Cancer 2005 [17] |
| IFO 2.5 gr/m2 1–2 or IFO 3 gr/m2 1–3 |
26 36 |
6 13 |
23 36 |
Verschoor AJ, Oncologist, 2019 [18] |
| IFO 14 g/m2 CI d 1–14 | 19 | 2/6 | 42 | Patel SR, JCO, 1997 [19] |
| IFO 14 g/m2 CI d 1–14 | 16 | 6/4 | 62 | Berrak SG, Ped Blood Cancer 2005 [20] |
| IFO 12 g/m2 CI d 1–14 | 30 | 1/2 | 10 | Harris MB, Med Ped Oncol 1995 [21] |
%ORR: overall response rate; CR: complete response; PR: partial response; JPHO: Journal of Pediatric Hematology and Oncology; nr: not reported.